Molecular Pharmacology Program

The David Scheinberg Lab

David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science.

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013), and cellular micropharmacies (Nature Chem.Biol., 2021).

Research Projects

Projects

Featured News

David Scheinberg, Chairman, Molecular Pharmacology and Chemistry Program

At Work: Center for Experimental Therapeutics Chair David Scheinberg

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.

Announcement

Pictured: Laurie Glimcher, Craig Thompson, Marc Tessier-Lavigne & Tadataka Yamada

Innovative Partnership Will Speed Drug Discovery and Development

Friday, October 25, 2013

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

Scientists ID Antibody That Might Boost Cancer Therapy

Thursday, April 4, 2013

Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...

View All Featured News

Publications

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5(176):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O’Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.

View All Publications

People

David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
MD, PhD, Johns Hopkins University School of Medicine

[email protected]: Email Address
646-888-2190: Office Phone
View physician profile: Physician profile

Members

Michael McDevitt — Michael R. McDevitt
Laboratory Member

Barbara de Mello — Barbara De Mello
Research Assistant

Michael X. Lau
Pediatric Hematology/Oncology Fellow

Josh Jaeyop Lee
Hematology/Oncology Fellow

Manish Malviya
Senior Research Scientist

Stephanie Pierre, BS — Stephanie Pierre
Graduate Student

Ekaterina Revskaya
Senior Research Scientist

Patrick Wallisch, MSc — Patrick Wallisch
Graduate Student

Lab Alumni

Emily C. Casey, BS — Emily C. Casey
Principal Scientific Communication Lead at Genentech, San Francisco, CA

Thomas J. Gardner, PhD — Thomas J. Gardner
Research Fellow

Graduate Student

Graduate Student

Research Technician

Graduate Student

Graduate Student

Graduate Student

Graduate Student

Mamadou A. Bah
Lab Rotation SEP-DEC 2020

Lab Affiliations

Lab News & Events

Tweets by @DASLab_MSKCC

Journal Club & Photo Album

Get in Touch

[email protected]

Lab Head Email
646-888-2190

Office Phone
646-888-2205

Lab Phone

Lab Resources

To learn more about Postdoc compensation and benefits at MSK, please visit https://www.mskcc.org/education-training/postdoctoral/resources-postdocs/compensation-benefits-resources

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

Actinium
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
Arvinas, Inc.
Ownership / Equity Interests
Bridge Medicines
Provision of Services (uncompensated)
CoImmune, Inc.
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
Ensysce Bioscience
Ownership / Equity Interests
Eureka Therapeutics Inc
Ownership / Equity Interests; Provision of Services (uncompensated)
Great Point Partners
Ownership / Equity Interests; Provision of Services

Iovance Biotherapeutics, Inc.
Ownership / Equity Interests
Lantheus Medical Imaging, Inc.
Ownership / Equity Interests
OncoPep, Inc.
Provision of Services
Pfizer, Inc.
Ownership / Equity Interests; Provision of Services
Repertoire Immune Medicines, Inc.
Provision of Services
Sapience Therapeutics, Inc.
Fiduciary Role/Position; Ownership / Equity Interests
Sellas Life Science Group
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures